Abbott and Enanta Pharmaceuticals announced complete data from the study known as "Pilot" - Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV) - showing that 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24). 82 percent of patients achieved SVR36. This is among the first 12-week, interferon-free HCV regimen with 36-week post-treatment data in genotype 1 patients. Results were presented today at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

CAMBRIDGE, England, March 20, 2012 /PRNewswire/ --